Companies / ATX

AMPLIA THERAPEUTICS LIMITED

ASX:ATXPharmaceuticals, Biotechnology & Life Sciences
513.3M shares on issueASX (delayed) · as of 28 July 2026$0.13price · delayed$71.9Mmarket cap · indicative
C
Dilution grade

Share count grew 87% in 24 months; 3 cash raises in 24 months; runway 4–8 quarters

Cash runway6.6 quarters of funding
Share-count growth (24m)87.2%
Raise cadence (24m)3 cash raises
Options & rights overhang27.3% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

AMPLIA THERAPEUTICS LIMITED's ordinary share count grew 87.2% between July 2024 and May 2026, to 513M shares. The company raised capital three times in that 24-month window for total disclosed proceeds of A$40.8M, most recently A$27.6M in July 2025. Options and rights on issue could convert into 140M new shares, equal to 27.3% of the current share count, with 0% in the money and the nearest expiry in October 2027. At the March 2026 quarter the company reported A$23.2M in available cash, equivalent to 6.6 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
27.3%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
6.6 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 513.3M per ASX (delayed) (28 July 2026).
412.0M449.2M486.4MDec 24Sept 25July 26Cash raise · 18 July 2025Cash raise · 4 July 2025

Cash runway

6.6 qtrs
More than four quarters of funding at the recent spend rate.
$23.2M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
15 July 20263G · unquotedATX : ORDINARY FULLY PAID513.3MAppendix 3G
15 July 20263G · unquotedATX : ORDINARY FULLY PAID513.3MAppendix 3G
12 May 20262A · quoted issueATX : ORDINARY FULLY PAID513.3MAppendix 2A
10 Nov 20253G · unquotedATX : ORDINARY FULLY PAID513.1MAppendix 3G
7 Oct 20253H · cancellationATX : ORDINARY FULLY PAID513.1MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

3 cash raises in the last 24 months · 0 in the last 12 months

$27.6M
Capital raise
18 July 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

27.3%
Total overhang · of current shares
0.0%
In the money · at current price
140.0M
Potential new shares
Oct 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
1 Sept 2025Warwick Bonner TongOther152k337k—3Y notice
1 Sept 2025Christopher John BurnsOther4.2M447k—3Y notice
1 Sept 2025Dr. Robert PeachOther652k241k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026Notice of Annual General Meeting/Proxy Form
15 July 2026Notification regarding unquoted securities - ATX
15 July 2026Notification regarding unquoted securities - ATX
12 July 2026Amplia Therapeutics Shareholder Webinar
6 July 2026Initial Director's Interest Notice - Brett Carter
5 July 2026Amplia Announces Appointment of Brett Carter to Board
30 June 2026Annual General Meeting to be held Friday 28 August 2026
29 June 2026Amplia Announces Changes to Board's Leadership Roles
24 June 2026Notice of Initial Substantial Holding from SOL
24 June 2026Becoming a substantial holder from PCG
29 May 2026Appendix 4G - Key to Corporate Governance Disclosures
29 May 2026Corporate Governance Statement 2026
29 May 2026$PPreliminary Final Report and Annual Report YE 31 March 2026
18 May 2026$PAmplia Launches First Stage of Pivotal Narmafotinib Trial
12 May 2026Notice under Section 708A(5)(e) of the Corporations Act
12 May 2026Application for quotation of securities - ATX
7 May 2026$PAmplia and ANZGOG announce Ovarian Cancer Study
27 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
21 Apr 2026ACCENT Trial Mature Data Presented at AACR Conference
8 Apr 2026Amplia MD Responds to Questions Regarding AMPLICITY Trial

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.